AABB

    AABB Develops New Fact Sheet for Clinicians Considering CCP to Treat COVID-19

    AABB has developed a fact sheet for clinicians considering the use of COVID-19 convalescent plasma that reflects the changes in the Food and Drug Administration’s revised emergency use authorization for CCP issued Dec. 28. The fact sheet provides recently updated information about the qualification of high-titer CCP, which patient populations are eligible to receive CCP, and the new option for outpatient treatment with CCP.

    Information about CCP and the revised EUA for blood centers is available in AABB’s Jan. 14 CCP toolkit

    Recent Stories
    AABB Releases Blood Component Cards as Member-Exclusive Offering

    AABB Develops New Fact Sheet for Clinicians Considering CCP to Treat COVID-19

    REGULATORY UPDATE: AABB Resource Highlights Crucial Regulatory Options Already Available from FDA to Support Blood Availability